|
 |
UroxatralThis page contains recent news articles, when available, and an overview of Uroxatral but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Uroxatral (when available) Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Alfuzosin results from a decrease in systemic vascular resistance and the parent compound Alfuzosin is primarily responsible for the antihypertensive activity. For the treatment of the signs and symptoms of benign prostatic hyperplasia Mechanism Of Action: Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. News Articles on Alfuzosin Family Doctor: Pumpkins can be used for more than pieD - Nov 11, 2009 The urologist put him on Uroxatral. He also continued to take saw palmetto and fish-oil capsules. His PSA gradually dropped to 3.7. ... Canton Repository Uroxatral Risks Not Adequately Disclosed in Advertisements: FDA Warns - Oct 29, 2009 The FDA issued a warning letter to drug maker Sanofi-Aventis over the use of certain promotional materials for its prostate drug Uroxatral, which were ... AboutLawsuits.com FDA Warns Sanofi Over Ad For Prostate Drug >SNY - Oct 27, 2009 The advertisement for Uroxatral, used to treat enlarged prostates, was a "tent card" and was presented with an outdated version of the drug's label, ... Wall Street Journal Sanofi Uroxatral Promotion Gets Untitled Letter - Nov 5, 2009 A “tent cardâ€? Sanofi-Aventis prepared to promote Uroxatral to treat benign prostatic hyperplasia presents overblown efficacy claims and should be withdrawn, ... FDA news (subscription) Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards - Oct 21, 2009 Company: Devito/Verdi -- Disease Awareness -- Uloric - Flares Aren't the Whole Story -- Company: GSW Worldwide -- Uroxatral - Uroxatral Patient Brochure ... Reuters French and Benelux stocks - Factors to watch on Oct 28 - Oct 28, 2009 ...the French drugmaker of distributing misleading promotional material on its Uroxatral treatment for urinary problems caused by an enlarged prostate. ... Forbes LEAD 1 USA - Avertissement à Sanofi concernant l'Uroxatral - Oct 27, 2009 PA: Cotation) qu'elle accuse d'employer du matériel promotionnel trompeur relatif à l'Uroxatral, un traitement de l'hypertrophie bénigne de la prostate. ... Reuters FDA, 사노피 ì „ë¦½ì„ ë¹„ëŒ€ì•½ ìš°ë¡œìž?트랄 íŒ?ì´‰ ê²½ê³ - Nov 1, 2009 ...김윤ì˜? 기ìž? FDA는 사노피-아벤티스사ì?˜ ì „ë¦½ì„ ë¹„ëŒ€ì¦? 치료약 ìš°ë¡œìž?트랄(Uroxatral: alfuzosin)ì—? 대한 íŒ?촉물ì—?ì„œ 오ë?„하는 표현ì?„ 지ì ?í•˜ê³ ê²½ê³ ì„œì‹ ì?„ 회사ì—? ... 메디포뉴스 FDA verwarnt Sanofi-Aventis wegen Werbekarte zu "Uroxatral" - Oct 27, 2009 Pharmahersteller Sanofi-Aventis verwarnt, weil in einer Werbung für das Medikament "Uroxatral" nicht auf die Risiken des Produkts hingewiesen werde. ... Finanztreff Le Cac 40 sous les 3.700 points avant les stats américaines - Oct 28, 2009 ...de Sanofi-Aventis qui gagne 0,62% à 52,35 euros en dépit d'un avertissement de l'autorité sanitaire américaine pour marketing trompeur sur l'Uroxatral. ... Les Échos Repli attendu à Paris, ArcelorMittal en première ligne - Oct 28, 2009 ...l'accusant de faire usage d'un marketing trompeur pour la promotion de l'Uroxatral, un traitement contre les troubles de la prostate. ... Les Échos What Texans Should Know about Cataract Surgery - Aug 18, 2009 ...doctor your complete medical and eye health history, including especially whether you are or have taken Flomax(R), Hytrin(R), Uroxatral(R) or Cadura(R). PR Newswire (press release) The hidden cost of obesity - Jul 12, 2009 Simvastatin 40 mg, Uroxatral 10 mg By Marshall Allen (contact) Before you read this story, please suspend any biases you may have about fat people. Las Vegas Sun BUYINS.NET: BLUD, NVO, RBN, ROS, SNY, CPII. Abnormal Price ... - Jun 26, 2009 Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. Trading Markets (press release) SNY-A Sanofi Safety Scare? - Jun 26, 2009 Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. TransWorldNews (press release) Sanofi-Aventis and AEterna Zentaris sign development agreement for ... - Mar 9, 2009 ...said: "This deal complements our strong presence in the urology space with Uroxatral (alfuzosin), Eligard (leuprolide) and Cialis (tadalafil), Trading Markets (press release) Sanofi-aventis and AEterna Zentaris Sign Agreement in the US - Mar 6, 2009 General Therapeutics Business Unit at sanofi-aventis US "This deal complements our strong presence in the urology space with Uroxatral(R) (alfuzosin), PR Newswire (press release) Incontinence, common among elderly, can be controlled - Jan 15, 2009 These include terazosin (Hytrin), doxazosin (Cardura), alfuzosin (Uroxatral), and tamsulosin (Flomax). Some of the older agents in this group can decrease Great Falls Tribune, Alpha-Blocker Therapy Shows No Benefit for Prostatitis - Dec 17, 2008 17 -- For chronic prostatitis-chronic pelvic pain syndrome, the alpha-blocker alfuzosin (Uroxatral) did no better than placebo, according to a randomized MedPage Today, Researchers rip open holiday myths - Dec 18, 2008 The international study of the drug alfuzosin, marketed under the brand name of Uroxatral, was led by Curtis Nickel of Queen's University in Kingston. Globe and Mail, World-Renowned Urologist, J. Francois Eid, MD, Expands Practice ... - Nov 21, 2008 Alpha blockers, which include Flomax, Cardura, Hytrin and Uroxatral are the most common way to treat BPH. They work by relaxing the prostate gland's smooth PR Web (press release), Acino: Erste neun Monate 2008 mit Rekordresultat - Oct 30, 2008 OxyContin von Mun-dipharma), Alfuzosin (Originalpräparat: Xatral XL, UroXatral von Sanofi-Aventis) und Amlodipin (Originalpräparat: Norvasc von Pfizer). Business-News (Pressemitteilung), BPH Drugs May Differ in Effects on Fracture Risk - Oct 7, 2008 Examples of selective alpha-blockers include tamsulosin (Flomax) and alfuzosin (UroXatral). The authors pointed out that "a well-known adverse effect of MedPage Today, Mike Schmidt urges men to cover all bases when it comes to health - Aug 21, 2008 Schmidt went to see a urologist and was prescribed to UROXATRAL. His urination problems are now under control and he wants to educate men all over the NECN, Tratando una próstata agrandada - Sep 6, 2008 ...incluyendo fÃnasteride (Prosear) y bloqueadores alfa, incluyendo terazosÃn (Hytrin), doxazosÃn (Cardura), tamusolina (Flomax) y alfuzosin (Uroxatral). CrÃtica, Treating an enlarged prostate - Aug 4, 2008 ...including terazosin (Hytrin), doxazosin (Cardura), tamsulosin (Flomax) and alfuzosin (Uroxatral). In addition to these tried and tested medications, Abilene Reporter-News, Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet ... - Aug 7, 2008 Tambocor(R); (flecainide); Uroxatral(R) (alfuzosin hydrochloride); Vascor(R) (bepridil); Versed(R) (midazolam); and Vfend(R) (voriconazole). FOXBusiness علاج تضخم البروستاتا - Aug 5, 2008 مثبطات ألÙ?ا: (terazosin (Hytrin), doxazosin (Cardura), (Flomax), prazosin (Uroxatral Ù?مثبطات ألÙ?ا تØسن الأعراض ولكنها لا تقلل Øجم التضخم. القبس, US Banks' Shaky Payouts, Sanofi Strategy, UK Press: Timshel - Jun 19, 2008 Last week, for instance, the company filed a lawsuit accusing India's Sun Pharmaceutical Industries Ltd. of violating a US patent for Uroxatral, Bloomberg Sanofi-Aventis Sues Sun Pharmaceutical Over Patent (Update2) - Jun 12, 2008 ...sued Indian rival Sun Pharmaceutical Industries Ltd., alleging infringement of a US patent for Uroxatral, used to treat an enlarged prostate gland. Bloomberg Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First ... - Jun 19, 2008 Together, we developed a game plan to manage my symptoms with Uroxatral(R) (alfuzosin HCl 10 mg extended-release tablets). Best known for leading the Earthtimes (press release), Eli Lilly and Sanofi Partner on Cialis - May 25, 2008 Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia, and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, RedOrbit, For Men, Relief in Sight - May 12, 2008 Alpha blockers like Flomax, Uroxatral, Hytrin and Cardura relax muscle fibers in the bladder and prostate. Other drugs like Proscar and Avodart, New York Times, Skyepharma PLC - Interim Management Statement - May 18, 2008 This decline was more than offset by strong growth in the USA, where sales of Uroxatral® were EUR26 million (GBP20 million), up 18.2%. Market Wire (press release) Sanofi-Aventis and Lilly in Cialis marketing pact - Mar 27, 2008 Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years,â€? Sanofi-Aventis markets Uroxatral Medical Marketing and Media, More Than Half of Patients Treated for Benign Prostatic ... - Apr 7, 2008 Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's PR Newswire (press release), Brand Names/Synonyms: Uroxatral is also known by the following brand names and/or synonyms: Uroxatral; Xatral Drug Category: Uroxatral is categorized under the following by the FDA: Antihypertensive Agents; Unclassified Therapeutic Agents (92:00.00); ATC:G04CA01 Dosage Forms: TABLET (EXTENDED-RELEASE) Absorption: Absorption is 50% lower under fasting conditions Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
